semaglutide shakes GLP-1 smoothie recipes: 15 high-protein smoothies for and tirzepatide users Current Fixation - by Lauren

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated a 15% average body weight reduction in clinical trials when used for weight management

Current theories concerning disease pathogenesis include an imbalance between protease and anti-protease activity, induced apoptosis of alveolar cells through deregulation of pathways involved in oxidative stress, chronic inflammation, and aberrant tissue remodeling that lead to the destruction of the extracellular matrix (ECM) in the lung [3, 4]

The present study emulated a target trial to avoid immortal time and selection bias, chose a second-line glucose-lowering therapy as an active comparator to reduce confounding by indication, used an outcome definition based only on primary care records to minimize detection bias due to differential hospitalizations, and implemented a lag time to mitigate bias due to reverse causality

G.WongJ

Altenkirch H, Stoltenburg-Didinger G, Wagner HM, et al